Gynecology Oncology
Ali D. Marhash; Mohammed S. Abdul-Razaq; Milal Muhammad AL-Jeborry; Wisam Jasim; Safa Khaleel khalaf
Articles in Press, Accepted Manuscript, Available Online from 13 April 2024
Abstract
Background and objective: Worldwide, cervical cancer stands as the leading cause of cancer-related fatalities. Cervical cancer is unequivocally attributed to the human papillomavirus (HPV) infection, which is both essential and adequate for its development. The particular prevalence of HPV in the population ...
Read More
Background and objective: Worldwide, cervical cancer stands as the leading cause of cancer-related fatalities. Cervical cancer is unequivocally attributed to the human papillomavirus (HPV) infection, which is both essential and adequate for its development. The particular prevalence of HPV in the population of Iraq is currently unclear. The objective of this study is to determine the frequency of HPV and identify the most common genotypes present in a sample of the Iraqi population. Materials and Methods: From November 2022 to December 2023, a total of 300 women with cervical anomalies, who were referred to the Gynecological Oncology Departments in multiple hospitals in Babylon and Baghdad, had cervical swabs collected. Real-time polymerase chain reaction was utilized to conduct HPV DNA testing on all specimens.Result: A total of 300 women between the ages of 20 and 60 were screened during the collecting period. The average age was 30 years. The prevalence of High-risk HPV was 16.7% overall. The age group of women between 30 and 40 years exhibited the highest overall prevalence of HPV. Our population survey indicates a higher prevalence of genotyping for HPV 16, 18, and 31.Conclusion: In this work, we used multiplex real-time pcr. This approach has numerous advantages, including HPV detection and genotyping to known prevalent genotypes as well as cost effective and no time consuming.
Sarah Khalifa; Maha E Muhammad; Rasha A. Khairy MD; Hala N Hosni; Ahmed M Abd E
Volume 3, Issue 1 , March and April 2018, , Pages 13-18
Abstract
Aims: Supporting evidences have been proposed that tumor initiating cells or cancer stem cells (CSCs) are principally sharing into tumor progress and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1), a stem cell marker, has currently been implicated in multiple human malignancies including ovarian carcinomas. ...
Read More
Aims: Supporting evidences have been proposed that tumor initiating cells or cancer stem cells (CSCs) are principally sharing into tumor progress and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1), a stem cell marker, has currently been implicated in multiple human malignancies including ovarian carcinomas. The aims of this study were to assess immunohistochemical (IHC) expression of ALDH1A1 in ovarian epithelial tumors, tracking stem cells during ovarian cancer development and its relation with the clinicopathological features of such tumors.
Materials and Methods: In this experimental study, 42 paraffin blocks of ovarian tumor cases were retrieved retrospectively from the department of pathology, faculty of medicine, Cairo University during January 2013 to January 2015. Ovarian tumor paraffin blocks included 14 benign cystadenomas 14 border line tumors and 14 carcinomas. IHC reactions were carried out by using ALDH1A1 monoclonal antibody. Cases were classified into two groups of low and high ALDH1A1 expression. The chi-squared test (χ2) was used and data analyzes by SPSS 22 software.
Findings: High ALDH1A1 expression was reported in 50.0% of benign cystadenomas, 50.0% of borderline tumors and 85.7% of ovarian carcinomas with significant positive association with ovarian carcinomas (p=0.025). In ovarian carcinomas, positive relationship was detected between high ALDHA1 expression and advancing tumor grades but it didn’t reach statistical significance (p=0.054), no any significant relations were detected between ALDH1A1 immunohistochemical expression and age of patients, the documented size, laterality, histologic types and FIGO stage in all tumors (p>0.05).
Conclusion: ALDH1A1 is a potential biomarker for detecting CSCs in ovarian carcinomas and a prognostic marker. Also, it may act as a target for future therapy.
